<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35999838</PMID><DateRevised><Year>2022</Year><Month>08</Month><Day>26</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2632-1297</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>4</Issue><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Brain communications</Title><ISOAbbreviation>Brain Commun</ISOAbbreviation></Journal><ArticleTitle>Exposure to phenytoin associates with a lower risk of post-COVID cognitive deficits: a cohort study.</ArticleTitle><Pagination><StartPage>fcac206</StartPage><MedlinePgn>fcac206</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">fcac206</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/braincomms/fcac206</ELocationID><Abstract><AbstractText>Post-COVID cognitive deficits (often referred to as 'brain fog') are common and have large impacts on patients' level of functioning. No specific intervention exists to mitigate this burden. This study tested the hypothesis, inspired by recent experimental research, that post-COVID cognitive deficits can be prevented by inhibiting receptor-interacting protein kinase. Using electronic health record data, we compared the cognitive outcomes of propensity score-matched cohorts of patients with epilepsy taking phenytoin (a commonly used receptor-interacting protein kinase inhibitor) versus valproate or levetiracetam at the time of COVID-19 diagnosis. Patients taking phenytoin at the time of COVID-19 were at a significantly lower risk of cognitive deficits in the 6 months after COVID-19 infection than a matched cohort of patients receiving levetiracetam (hazard ratio 0.78, 95% confidence interval 0.63-0.97, <i>P</i>&#x2009;=&#x2009;0.024) or valproate (hazard ratio 0.73, 95% confidence interval 0.58-0.93, <i>P</i>&#x2009;=&#x2009;0.011). In secondary analyses, results were robust when controlling for subtype of epilepsy, and showed specificity to cognitive deficits in that similar associations were not seen with other 'long-COVID' outcomes such as persistent breathlessness or pain. These findings provide pharmacoepidemiological support for the hypothesis that receptor-interacting protein kinase signaling is involved in post-COVID cognitive deficits. These results should prompt empirical investigations of receptor-interacting protein kinase inhibitors in the prevention of post-COVID cognitive deficits.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2022. Published by Oxford University Press on behalf of the Guarantors of Brain.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Taquet</LastName><ForeName>Maxime</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-8987-952X</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harrison</LastName><ForeName>Paul J</ForeName><Initials>PJ</Initials><Identifier Source="ORCID">0000-0002-6719-1126</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Brain Commun</MedlineTA><NlmUniqueID>101755125</NlmUniqueID><ISSNLinking>2632-1297</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Mpro</Keyword><Keyword MajorTopicYN="N">RIPK signaling</Keyword><Keyword MajorTopicYN="N">brain fog</Keyword><Keyword MajorTopicYN="N">endotheliopathy</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>1</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>24</Day><Hour>1</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>25</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>8</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35999838</ArticleId><ArticleId IdType="pmc">PMC9384796</ArticleId><ArticleId IdType="doi">10.1093/braincomms/fcac206</ArticleId><ArticleId IdType="pii">fcac206</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Taquet M, Dercon Q, Luciano S, Geddes JR, Husain M, Harrison PJ. Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Med. 2021;18(9):e1003773.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8478214</ArticleId><ArticleId IdType="pubmed">34582441</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-Month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: A retrospective cohort study using electronic health records. Lancet Psychiatry 2021;8(5):416&#x2013;427.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8023694</ArticleId><ArticleId IdType="pubmed">33836148</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, Assaf GS, McCorkell L, et al. . Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine 2021;38:101019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans RA, McAuley H, Harrison EM, et al. . Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): A UK multicentre, prospective cohort study. Lancet Respir Med. 2021;9(11):1275&#x2013;1287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8497028</ArticleId><ArticleId IdType="pubmed">34627560</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham EL, Clark JR, Orban ZS, et al. . Persistent neurologic symptoms and cognitive dysfunction in non-hospitalized COVID-19 &#x201c;long haulers&#x201d;. Ann Clin Transl Neurol. 2021;8(5):1073&#x2013;1085.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8108421</ArticleId><ArticleId IdType="pubmed">33755344</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampshire A, Trender W, Chamberlain SR, et al. . Cognitive deficits in people who have recovered from COVID-19. EClinicalMedicine 2021;39:101044.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8298139</ArticleId><ArticleId IdType="pubmed">34316551</ArticleId></ArticleIdList></Reference><Reference><Citation>Balcom EF, Nath A, Power C. Acute and chronic neurological disorders in COVID-19: Potential mechanisms of disease. Brain 2021;144(12):3576&#x2013;3588.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8719840</ArticleId><ArticleId IdType="pubmed">34398188</ArticleId></ArticleIdList></Reference><Reference><Citation>Wenzel J, Lampe J, M&#xfc;ller-Fielitz H, et al. . The SARS-CoV-2 main protease Mpro causes microvascular brain pathology by cleaving NEMO in brain endothelial cells. Nat Neurosci. 2021;24(11):1522&#x2013;1533.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8553622</ArticleId><ArticleId IdType="pubmed">34675436</ArticleId></ArticleIdList></Reference><Reference><Citation>Martens S, Hofmans S, Declercq W, Augustyns K, Vandenabeele P. Inhibitors targeting RIPK1/RIPK3: Old and new drugs. Trends Pharmacol Sci. 2020;41(3):209&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">32035657</ArticleId></ArticleIdList></Reference><Reference><Citation>Von M&#xe4;ssenhausen A, Tonnus W, Himmerkus N, et al. . Phenytoin inhibits necroptosis. Cell Death Dis. 2018;9(3):1&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5834524</ArticleId><ArticleId IdType="pubmed">29500402</ArticleId></ArticleIdList></Reference><Reference><Citation>Moerke C, Jaco I, Dewitz C, et al. . The anticonvulsive Phenhydan&#xae; suppresses extrinsic cell death. Cell Death Differ. 2019;26(9):1631&#x2013;1645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6748113</ArticleId><ArticleId IdType="pubmed">30442947</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenze EJ, Mattar C, Zorumski CF, et al. . Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: A randomized clinical trial. JAMA 2020;324(22):2292&#x2013;2300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7662481</ArticleId><ArticleId IdType="pubmed">33180097</ArticleId></ArticleIdList></Reference><Reference><Citation>Vai B, Mazza MG, Colli CD, et al. . Mental disorders and risk of COVID-19-related mortality, hospitalisation, and intensive care unit admission: A systematic review and meta-analysis. Lancet Psychiatry 2021;8(9):797&#x2013;812.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8285121</ArticleId><ArticleId IdType="pubmed">34274033</ArticleId></ArticleIdList></Reference><Reference><Citation>Fosb&#xf8;l EL, Butt JH, &#xd8;stergaard L, et al. . Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with COVID-19 diagnosis and mortality. JAMA 2020;324(2):168&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7305566</ArticleId><ArticleId IdType="pubmed">32558877</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenbaum PR, Rubin DB. Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Stat 1985;39(1):33&#x2013;38.</Citation></Reference><Reference><Citation>Haukoos JS, Lewis RJ. The propensity score. JAMA 2015;314(15):1637&#x2013;1638.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4866501</ArticleId><ArticleId IdType="pubmed">26501539</ArticleId></ArticleIdList></Reference><Reference><Citation>VanderWeele TJ, Ding P. Sensitivity analysis in observational research: Introducing the E-value. Ann Intern Med. 2017;167(4):268&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pubmed">28693043</ArticleId></ArticleIdList></Reference><Reference><Citation>Royston P, Parmar MKB. A simulation study comparing the power of nine tests of the treatment effect in randomized controlled trials with a time-to-event outcome. Trials 2020;21(1):315.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7132898</ArticleId><ArticleId IdType="pubmed">32252820</ArticleId></ArticleIdList></Reference><Reference><Citation>Airaksinen EM, Matilainen R, Mononen T, et al. . A population-based study on epilepsy in mentally retarded children. Epilepsia 2000;41(9):1214&#x2013;1220.</Citation><ArticleIdList><ArticleId IdType="pubmed">10999562</ArticleId></ArticleIdList></Reference><Reference><Citation>Pantoni L. Cerebral small vessel disease: From pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol. 2010;9(7):689&#x2013;701.</Citation><ArticleIdList><ArticleId IdType="pubmed">20610345</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomer B, Wagner K, Frings L, et al. . The influence of antiepileptic drugs on cognition: A comparison of levetiracetam with topiramate. Epilepsy Behav. 2007;10(3):486&#x2013;494.</Citation><ArticleIdList><ArticleId IdType="pubmed">17409025</ArticleId></ArticleIdList></Reference><Reference><Citation>Magalh&#xe3;es JC, Gongora M, Vicente R, et al. . The influence of levetiracetam in cognitive performance in healthy individuals: Neuropsychological, behavioral and electrophysiological approach. Clin Psychopharmacol Neurosci. 2015;13(1):83&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4423160</ArticleId><ArticleId IdType="pubmed">25912541</ArticleId></ArticleIdList></Reference><Reference><Citation>Jokeit H, Kr&#xe4;mer G, Ebner A. Do antiepileptic drugs accelerate forgetting? Epilepsy Behav 2005;6(3):430&#x2013;432.</Citation><ArticleIdList><ArticleId IdType="pubmed">15820354</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu SX, Tyagi T, Jain K, et al. . Thrombocytopathy and endotheliopathy: Crucial contributors to COVID-19 thromboinflammation. Nat Rev Cardiol. 2021;18(3):194&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7675396</ArticleId><ArticleId IdType="pubmed">33214651</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuadrado-Godia E, Dwivedi P, Sharma S, et al. . Cerebral small vessel disease: A review focusing on pathophysiology, biomarkers, and machine learning strategies. J Stroke Cerebrovasc Dis. 2018;20(3):302&#x2013;320.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6186915</ArticleId><ArticleId IdType="pubmed">30309226</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>